Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
90 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Brain Tumor - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Brain Tumor - Pipeline Review, H2 2014', provides an overview of the Brain Tumor's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Brain Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Tumor and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Brain Tumor - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Brain Tumor and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Brain Tumor pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Tumor - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Tumor pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Brain Tumor Overview 8 Therapeutics Development 9 Pipeline Products for Brain Tumor - Overview 9 Pipeline Products for Brain Tumor - Comparative Analysis 10 Brain Tumor - Therapeutics under Development by Companies 11 Brain Tumor - Therapeutics under Investigation by Universities/Institutes 13 Brain Tumor - Pipeline Products Glance 14 Clinical Stage Products 14 Early Stage Products 15 Brain Tumor - Products under Development by Companies 16 Brain Tumor - Products under Investigation by Universities/Institutes 17 Brain Tumor - Companies Involved in Therapeutics Development 18 Chong Kun Dang Pharmaceutical Corp. 18 Pfizer Inc. 19 Bayer AG 20 Nanobiotix 21 Hutchison MediPharma Limited 22 Siena Biotech S.p.A. 23 Oncovir, Inc. 24 DEKK-TEC, Inc. 25 SignPath Pharma Inc 26 CalAsia Pharmaceuticals, Inc. 27 Brain Tumor - Therapeutics Assessment 28 Assessment by Monotherapy Products 28 Assessment by Combination Products 29 Assessment by Target 30 Assessment by Mechanism of Action 33 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 DM-CHOC-PEN - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 beloranib - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Poly-ICLC - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 GliAtak - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 indoximod - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 dianhydrogalactitol - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 HMPL-813 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 DC/AAT + DC/AAT-Flu + DC/KLH - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 CIGB-128 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Cell Therapy for Brain Cancer - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 HOOI - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Tankyrase/Wnt Inhibitors - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Bispecific Antibody for Brain Tumor - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Bay-846 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 NBTX-TOPO - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 VO-100 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 PF-06463922 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Small Molecules to Inhibit Hsp90 Alpha and TRAP1 for Brain Cancer - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Polymeric Nanocurcumin - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 Monoclonal Antibody to Inhibit EGFR for Brain Tumor - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Brain Tumor - Recent Pipeline Updates 68 Brain Tumor - Dormant Projects 79 Brain Tumor - Discontinued Products 80 Brain Tumor - Product Development Milestones 81 Featured News & Press Releases 81 May 20, 2014: Oncolytics Biotech Collaborators to Present Positive Brain Cancer Clinical Trial Data at the 50th Annual ASCO Meeting 81 Dec 16, 2013: Angiochem Demonstrates Peptide Antibody Conjugate That Successfully Crosses the Blood Brain Barrier and Increases Survival in HER-2 Positive Brain Tumors 81 Nov 16, 2013: Burzynski Clinic Presents Over Five Years Survival Data From Phase II Trials of ANP for Inoperable Brain Tumors at the Congress 82 Mar 18, 2013: Anti-nausea Drug Halts Growth Of Brain Tumors, Research Finds 82 Dec 17, 2012: new immune therapy successfully treats brain tumors in mice 83 Aug 18, 2011: Cell Therapeutics Announces Enrollment Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 84 Jun 06, 2011: CTI Announces Interim Results Of Phase II Study Of OPAXIO In Combination With Temozolomide And Radiotherapy In Brain Tumors 85 Feb 02, 2011: Antisense Pharma Receives Approval For Clinical Studies In South Korea And Taiwan In Malignant Brain Tumors 85 Nov 02, 2010: Antisense Pharma's Trabedersen In Malignant Brain Tumors: Phase IIb Data Published In Neuro-Oncology 86 Oct 29, 2010: Novartis Drug Afinitor Approved by FDA as First Medication for Children and Adults with a Benign Brain Tumor Associated with Tuberous Sclerosis. 87 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 90 Disclaimer 90
List of Tables Number of Products under Development for Brain Tumor, H2 2014 9 Number of Products under Development for Brain Tumor - Comparative Analysis, H2 2014 10 Number of Products under Development by Companies, H2 2014 12 Number of Products under Investigation by Universities/Institutes, H2 2014 13 Comparative Analysis by Clinical Stage Development, H2 2014 14 Comparative Analysis by Early Stage Development, H2 2014 15 Products under Development by Companies, H2 2014 16 Products under Investigation by Universities/Institutes, H2 2014 17 Brain Tumor - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2014 18 Brain Tumor - Pipeline by Pfizer Inc., H2 2014 19 Brain Tumor - Pipeline by Bayer AG, H2 2014 20 Brain Tumor - Pipeline by Nanobiotix, H2 2014 21 Brain Tumor - Pipeline by Hutchison MediPharma Limited, H2 2014 22 Brain Tumor - Pipeline by Siena Biotech S.p.A., H2 2014 23 Brain Tumor - Pipeline by Oncovir, Inc., H2 2014 24 Brain Tumor - Pipeline by DEKK-TEC, Inc., H2 2014 25 Brain Tumor - Pipeline by SignPath Pharma Inc, H2 2014 26 Brain Tumor - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2014 27 Assessment by Monotherapy Products, H2 2014 28 Assessment by Combination Products, H2 2014 29 Number of Products by Stage and Target, H2 2014 32 Number of Products by Stage and Mechanism of Action, H2 2014 35 Number of Products by Stage and Route of Administration, H2 2014 37 Number of Products by Stage and Molecule Type, H2 2014 39 Brain Tumor Therapeutics - Recent Pipeline Updates, H2 2014 68 Brain Tumor - Dormant Projects, H2 2014 79 Brain Tumor - Discontinued Products, H2 2014 80
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.